Print Friendly Page

Protocol No. ANBL1232

Principal Investigator DeSantes, Kenneth

Phase III

Age Group Children

Scope National

Sponsor Type National

Title Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma


Applicable Disease Sites Neuroblastoma

Therapies Involved Cytotoxic Chemotherapy; Surgery

Drugs Involved adr (doxorubicin); adria (doxorubicin); adriamycin (doxorubicin); carboplatin; cbdca (carboplatin); cpm (cyclophosphamide); ctx (cyclophosphamide); cyclophosphamide; cytoxan (cyclophosphamide); dox (doxorubicin); doxorubicin; etoposide; filgrastim; g-csf (filgrastim); gcsf (filgrastim); neosar (cyclophosphamide); neupogen (filgrastim); paraplatin (carboplatin); vepesid (etoposide); vp-16 (etoposide)

Status Open

Participating Institutions Gundersen Health System; UW Hospital and Clinics